Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01571089
Other study ID # OLL-189011
Secondary ID
Status Completed
Phase N/A
First received March 26, 2012
Last updated May 19, 2015
Start date March 2012
Est. completion date October 2014

Study information

Verified date May 2015
Source Örebro County Council
Contact n/a
Is FDA regulated No
Health authority Sweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

The main interest in this study is to investigate if it is possible to use strategies from Dialectical Behavior Therapy (DBT) to increase effectiveness of ordinary Cognitive Behavioral Therapy (CBT) for patients with anxiety disorders. For the patients included in this study, previous exposure-based treatment should have been unsuccessful (drop-out, relapse or lack of positive results after treatment).


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Currently diagnosed with an anxiety disorder. To be included, the level of anxiety in a critical situation should be high and of a more acute type, unlike the lower more generalized anxiety in for example generalized anxiety disorder.

- Previous exposure-based treatment should have been unsuccessful (drop-out, relapse or lack of positive results after treatment).

Exclusion Criteria:

- Severe depression.

- Psychotic disorder.

- A documented neuropsychiatric diagnosis.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
DBT-inspired anxiety treatment
In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.

Locations

Country Name City State
Sweden Psychiatric Clinic Hallsberg Örebro County

Sponsors (1)

Lead Sponsor Collaborator
Örebro County Council

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in anxiety (Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., Louis, B., 2003). A modified 6-item questionnaire measuring changes in different aspects of anxiety during the day. Originally developed to measure social anxiety. Every day during baseline phase, an expected average of 3 weeks. Everyday during treatment, an expected duration of 24 weeks. Everyday during 6 mo. follow-up, an expected average of 3 weeks. No
Secondary Positive Negative Affect Scale (PANAS), (Watson, Clark & Tellegan, 1988). A 20-item questionnaire measuring positive and negative affect during the past week. The questionnaire is used to evaluate changes in positive and negative affect. Once a week during baseline phase, an expected average of 3 weeks. Once a week during treatment, an expected duration of 24 weeks. Once a week during 6 mo. follow-up, an expected average of 3 weeks. No
Secondary Overall Anxiety Severity and Impairment Scale (OASIS), (Barlow, 2011). A 5-item questionnaire measuring different aspects of anxiety during the past week. The questionnaire is used to evaluate changes in anxiety symtoms. Once a week during baseline phase, an expected average of 3 weeks. Once a week during treatment, an expected duration of 24 weeks. Once a week during 6 mo. follow-up, an expected average of 3 weeks. No
Secondary Overall Depression Severity and Impairment Scale (ODSIS), (Barlow, 2011). A 5-item questionnaire measuring different aspects of depression during the past week. The questionnaire is used to evaluate changes in depressive symtoms. Once a week during baseline phase, an expected average of 3 weeks. Once a week during treatment, an expected duration of 24 weeks. Once a week during 6 mo. follow-up, an expected average of 3 weeks. No
Secondary Difficulties in Emotion Regulation Scale (DERS), (Gratz & Roemer, 2004). A 36-item self-report instrument that measure changes in difficulties in emotion regulation. Five times total. Pre baseline, post baseline/post treatment, after 14 weeks of treatment, post treatment and at 6 mo. follow-up. No
Secondary Five Fazet Mindfulness Questionnaire (Baer, Smith, Hopkins, Krietemeyer, & Toney, 2006). A 39-item questionnaire measuring changes in different aspects of mindfulness. Five times total. Pre baseline, post baseline/post treatment, after 14 weeks of treatment, post treatment and at 6 mo. follow-up. No
Secondary WHOQOL-BREF (Skevington, Lofty, O´Connel & WHOQOL Group, 2004). A 26-item self-report instrument that measure changes in quality of life. Five times total. Pre baseline, post baseline/post treatment, after 14 weeks of treatment, post treatment and at 6 mo. follow-up. No
Secondary Structured Clinical Interview for DSM-IV-I (SCID-I), (First, Spitzer, Gibbon, & Williams, 2001). A structural interview assessing axis-I disorders. This instrument is used to evaluate changes in axis-I disorders in the patients. Pre- and post treatment No